NKGN insider transaction filings
NKGen Biotech, Inc. — 14 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-06-02. Screen NKGN transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for NKGN between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — NKGen Biotech, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-06-02 | 4 | CFIC-2015 NV Family Investments, LLC — 10% owner Cherng Andrew Jin-Chan — 10% owner CHERNG PEGGY — 10% owner | Purchase (P): 19,669,552 @ $0.13 · Purchase (P): 39,339,103 (derivative) @ $0.13 | EDGAR |
| 2025-05-07 | 4 | Song Paul Y. — Chief Executive Officer | Purchase (P): 20,849,725 @ $0.13 · Purchase (P): 41,699,449 (derivative) @ $0.13 | EDGAR |
| 2024-12-26 | 4 | Graf Acquisition Partners IV LLC — 10% owner Graf James A — Interim CFO, 10% owner | Other (J): 63,634 @ $0 · Disposition to issuer (D): 757,942 (derivative) · Disposition to issuer (D): 93,334 (derivative) | EDGAR |
| 2024-12-23 | 4 | Graf Acquisition Partners IV LLC — 10% owner Graf James A — Interim CFO, 10% owner | Other (J): 97,232 @ $0 · Other (J): 83,214 @ $0 · Other (J): 110,157 @ $0 · Disposition to issuer (D): 713,357 (derivative) · Disposition to issuer (D): 1,212,707 (derivative) · Disposition to issuer (D): 66,667 (derivative) · +2 more | EDGAR |
| 2024-12-10 | 4 | Klowden Michael — Director | Grant/award (A): 300,000 (derivative) @ $0 · Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2024-12-10 | 4 | Song Paul Y. — Chief Executive Officer | Grant/award (A): 2,000,000 (derivative) @ $0 | EDGAR |
| 2024-12-10 | 4 | Scott Kathleen D. — Director | Grant/award (A): 300,000 (derivative) @ $0 · Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2024-12-10 | 4 | Graf James A — Chief Financial Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2024-07-18 | 4 | Gottardis Marco — Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Kim Yong Man — CSO and CIO | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Song Paul Y. — Chief Executive Officer, Director | Grant/award (A): 1,260,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Gagnon Pierre — Chief Operating Officer | Grant/award (A): 360,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Klowden Michael — Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Scott Kathleen D. — Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — NKGen Biotech, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NKGN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →